SOURCE: Lpath, Inc.

Lpath, Inc.

December 20, 2010 08:33 ET

Lpath to Hold Investor Update Conference Call on Tuesday, December 21, 2010 at 1:00 p.m. ET

SAN DIEGO, CA--(Marketwire - December 20, 2010) - Lpath, Inc. (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, will hold a conference call on Tuesday, December 21, 2010 at 1:00 p.m. Eastern time to discuss the newly forged partnership with Pfizer, Inc. (NYSE: PFE), whereby Lpath has granted to Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP™, Lpath's first-in-class monoclonal antibody product candidate.

iSONEP is currently being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other ophthalmology disorders.

Lpath's president and CEO, Scott Pancoast, will host the call and also provide a general company update, which will be followed by a question-and-answer period.

To participate in the call, dial the conference number 5-10 minutes prior to the start time and provide the conference ID provided below.

Date: Tuesday, December 21, 2010
Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time)
Dial-In Number: 1-800-894-5910
International: 1-785-424-1052
Conference ID: 7LPATH

Internet simulcast and replay:

If you have any difficulty connecting with the conference call, please contact the Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available from 4:00 p.m. Eastern time on the same day until January 27, 2011 by dialing the replay number and passcode as follows:

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Passcode: 12024

About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is advancing three drug candidates, two of which -- iSONEP for wet AMD and ASONEP for cancer -- have completed Phase 1 clinical trials. For more information, visit

Contact Information